Sugi Predict

Sugi Predict / Targets / FASN

FASN

Fatty acid synthase · P49327 · FASN on Sugi Atlas →

53,605 patent compounds predicted against FASN, 29,501 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10472 SCHEMBL10472 0.57 20/20
SCHEMBL10473 SCHEMBL10473 0.57 20/20
SCHEMBL10563 SCHEMBL10563 0.57 20/20
SCHEMBL10564 SCHEMBL10564 0.57 20/20
SCHEMBL10344 SCHEMBL10344 0.55 20/20
SCHEMBL10345 SCHEMBL10345 0.55 20/20
SCHEMBL10312 SCHEMBL10312 0.54 20/20
SCHEMBL10313 SCHEMBL10313 0.54 20/20
SCHEMBL10478 SCHEMBL10478 0.53 20/20
SCHEMBL10479 SCHEMBL10479 0.53 20/20
SCHEMBL14348 SCHEMBL14348 0.56 19/20
SCHEMBL14823 SCHEMBL14823 0.56 19/20
SCHEMBL14712 SCHEMBL14712 0.54 19/20
SCHEMBL14784 SCHEMBL14784 0.51 19/20
SCHEMBL10905 SCHEMBL10905 0.61 18/20
SCHEMBL10906 SCHEMBL10906 0.61 18/20
SCHEMBL14292 SCHEMBL14292 0.59 18/20
SCHEMBL10303 SCHEMBL10303 0.57 18/20
SCHEMBL10304 SCHEMBL10304 0.57 18/20
SCHEMBL10921 SCHEMBL10921 0.56 18/20

Clinical trials — most relevant to FASN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer PHASE4WITHDRAWN
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) PHASE4COMPLETED
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver PHASE2COMPLETED
Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia PHASE2COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) PHASE2COMPLETED
Liver Positron Emission Tomography (PET) Study of Non Alcoholic Fatty Liver Disease EARLY_PHASE1COMPLETED
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction nanUNKNOWN
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
Effect of Dietary SFA and Fructose on Hepatic Insulin Sensitivity nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Monitoring of Hepatic Fat Metabolism Using Magnetic Resonance Methods nanCOMPLETED
De Novo Lipogenesis in Severity of NAFLD nanCOMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome nanUNKNOWN
Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD) nanCOMPLETED
Androgens and NAFLD Longitudinal Cohort Study nanRECRUITING
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis nanCOMPLETED
Screening of Healthy Adults for Genetic Variations That Control Fatty Acid Processing nanCOMPLETED
Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance nanCOMPLETED
The Role of Sugars in Fat Accumulation in the Liver nanRECRUITING
Lifestyle Intervention in Preparation for Pregnancy (LIPP) nanCOMPLETED
Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury nanCOMPLETED
Use of MCT Oil for Enhancement of Weight Loss in Obese Patients nanCOMPLETED
Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids nanUNKNOWN
Hepatic Energy Fluxes in NASH and NAS Patients nanACTIVE_NOT_RECRUITING
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Impact Of Choline in Patients With NAFLD nanUNKNOWN
Tissue Lipids and Insulin Resistance nanWITHDRAWN
Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a FASN binder may also engage these)

ProteinNameSimilarity
P19096 — 1.000 P19096 →
P12785 — 1.000 P12785 →
Q71SP7 — 0.994 Q71SP7 →
P12276 — 0.986 P12276 →
Q8R123 — 0.973 Q8R123 →
Q2YDP8 — 0.970 Q2YDP8 →
A0A1W5T1T1 — 0.970 A0A1W5T1T1 →
S7ZFK6 — 0.970 S7ZFK6 →
A0A0U5GK88 — 0.968 A0A0U5GK88 →
K3VA96 — 0.968 K3VA96 →
P9WEZ4 — 0.968 P9WEZ4 →
A0A6F9DXA0 — 0.967 A0A6F9DXA0 →
Q7TNG8 — 0.967 Q7TNG8 →
Q86U10 — 0.967 Q86U10 →
P27718 — 0.967 P27718 →
TARS2 Threonine--tRNA ligase, mitochondrial 0.967 landscape →
A0A1L9WQM9 — 0.967 A0A1L9WQM9 →
A0A1W5T1U1 — 0.967 A0A1W5T1U1 →
P80041 — 0.967 P80041 →
A0A0U4ZX08 — 0.967 A0A0U4ZX08 →
Q0CZH1 — 0.967 Q0CZH1 →
O75191 — 0.966 O75191 →
P0DXV8 — 0.966 P0DXV8 →
A0A6J4B487 — 0.966 A0A6J4B487 →
Q86WU2 — 0.966 Q86WU2 →
A0A1U8CC89 — 0.966 A0A1U8CC89 →
O95396 — 0.966 O95396 →
A0A2Z5TM64 — 0.966 A0A2Z5TM64 →
A0A7R7WPZ6 — 0.966 A0A7R7WPZ6 →
Q5RCH4 — 0.966 Q5RCH4 →